Lisanti Capital Growth LLC Invests $6.97 Million in Adaptive Biotechnologies Corporation $ADPT

Lisanti Capital Growth LLC purchased a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 325,155 shares of the company’s stock, valued at approximately $6,975,000. Adaptive Biotechnologies comprises approximately 1.5% of Lisanti Capital Growth LLC’s holdings, making the stock its 14th biggest position.

Other large investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new position in Adaptive Biotechnologies during the fourth quarter valued at approximately $28,000. EverSource Wealth Advisors LLC lifted its stake in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the last quarter. Assetmark Inc. grew its position in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after acquiring an additional 2,708 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies in the fourth quarter worth approximately $51,000. Finally, Strive Financial Group LLC acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth $52,000. Institutional investors own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

ADPT has been the topic of a number of recent research reports. Morgan Stanley raised their price target on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Piper Sandler raised their target price on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, TD Cowen boosted their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.42.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $25.49 on Thursday. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16. The firm’s fifty day simple moving average is $21.75 and its 200 day simple moving average is $17.24. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The firm has a market capitalization of $4.07 billion, a PE ratio of -62.17 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same period in the prior year, the firm earned ($0.17) EPS. The firm’s revenue was up 21.5% on a year-over-year basis. On average, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Insiders Place Their Bets

In related news, insider Sharon Benzeno sold 154,768 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the completion of the sale, the insider owned 221,278 shares in the company, valued at $4,677,816.92. This represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 321,324 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $25.08, for a total value of $8,058,805.92. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at $54,687,391.44. This trade represents a 12.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,031,661 shares of company stock valued at $45,910,868 in the last ninety days. Company insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.